Interstitial pneumonitis associated with trastuzumab emtansine

被引：11

作者：

Alkan, Ali ^{[1
]}

机构：

[1] Osmaniye Publ Hosp, Med Oncol, Merkez, Osmaniye, Turkey

来源：

JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2019年 / 25卷 / 07期

关键词：

Trastuzumab emtansine; interstitial pneumonitis; breast cancer; BREAST-CANCER;

D O I：

10.1177/1078155218813716

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Trastuzumab emtansine is an antibody-drug conjugate that is effective in human epidermal growth factor receptor-2 expressing advanced breast cancer. Trastuzumab emtansine is generally well tolerated and grade 3-4 toxicities are rare. Pulmonary complications were rarely reported. Here we present a patient presenting with dyspnea after trastuzumab emtansine therapy and treated with a diagnosis of interstitial pneumonitis.

引用

页码：1798 / 1800

页数：3

共 15 条

[1] Delayed Paclitaxel-Trastuzumab-Induced Interstitial Pneumonitis in Breast Cancer [J].

Abulkhair, Omalkhair ;

El Melouk, Wael .

CASE REPORTS IN ONCOLOGY, 2011, 4 (01) :186-191

[2] Interstitial lung disease [J].

Antoniou, Katerina M. ;

Margaritopoulos, George A. ;

Tomassetti, Sara ;

Bonella, Francesco ;

Costabel, Ulrich ;

Poletti, Venerino .

EUROPEAN RESPIRATORY REVIEW, 2014, 23 (131) :40-54

[3] Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature [J].

Bielopolski, Dana ;

Evron, Ella ;

Moreh-Rahav, Osnat ;

Landes, Michal ;

Stemmer, Salomon M. ;

Salamon, Francis .

JOURNAL OF CHEMOTHERAPY, 2017, 29 (02) :113-117

[4]

Costa R, 2017, CASE REP ONCOL, V10, P524, DOI 10.1159/000477340

[5] Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review [J].

Dawood, Shaheenah ;

Broglio, Kristine ;

Buzdar, Aman U. ;

Hortobagyi, Gabriel N. ;

Giordano, Sharon H. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :92-98

[6] Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial [J].

Krop, Ian E. ;

Kim, Sung-Bae ;

Gonzalez Martin, Antonio ;

LoRusso, Patricia M. ;

Ferrero, Jean-Marc ;

Badovinac-Crnjevic, Tanja ;

Hoersch, Silke ;

Smitt, Melanie ;

Wildiers, Hans .

LANCET ONCOLOGY, 2017, 18 (06) :743-754

[7]

Kuip E, 2009, NETH J MED, V67, P237

[8] Telangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine A Case Report [J].

Kwon, Younghoon ;

Gomberg-Maitland, Mardi ;

Pritzker, Marc ;

Thenappan, Thenappan .

CHEST, 2016, 149 (04) :E103-E105

[9] A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].

NARANJO, CA ;

BUSTO, U ;

SELLERS, EM ;

SANDOR, P ;

RUIZ, I ;

ROBERTS, EA ;

JANECEK, E ;

DOMECQ, C ;

GREENBLATT, DJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245

[10] Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study [J].

Perez, Edith A. ;

Barrios, Carlos ;

Eiermann, Wolfgang ;

Toi, Masakazu ;

Im, Young-Hyuck ;

Conte, Pierfranco ;

Martin, Miguel ;

Pienkowski, Tadeusz ;

Pivot, Xavier ;

Burris, Howard, III ;

Petersen, Jennifer A. ;

Stanzel, Sven ;

Strasak, Alexander ;

Patre, Monika ;

Ellis, Paul .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) :141-+

← 1 2 →